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USP17 is required for trafficking and
oncogenic signaling of mutant EGFR in
NSCLC cells
Aidan P. McCann1, Peter Smyth2, Francesco Cogo2, William J. McDaid2, Lai Jiang2, Jia Lin1, Emma Evergren2,
Roberta E. Burden1, Sandra Van Schaeybroeck2, Christopher J. Scott2 and James F. Burrows1*
Abstract
Background: The deubiquitinase USP17 is overexpressed in NSCLC and has been shown to be required for the
growth and motility of EGFR wild-type (WT) NSCLC cells. USP17 is also required for clathrin-mediated endocytosis of
EGFR. Here, we examine the impact of USP17 depletion on the growth, as well as EGFR endocytosis and signaling,
of EGFR mutant (MT) NSCLC cells. In particular, we examine NSCLC cells harboring an EGFR activating exon 19
deletion (HCC827), or both the L858R activating mutation and the T790M resistance gatekeeper mutation (H1975)
which renders them resistant to EGFR tyrosine kinase inhibitors (TKIs).
Methods: MTT, trypan blue and clonogenic assays, confocal microscopy, Western blotting and cell cycle analysis
were performed.
Results: USP17 depletion blocks the growth of EGFRMT NSCLC cells carrying either the EGFR exon 19 deletion, or
L858R/T790M double mutation. In contrast to EGFRWT cells, USP17 depletion also triggers apoptosis of EGFRMT
NSCLC cells. USP17 is required for clathrin-mediated endocytosis in these EGFRMT NSCLC cells, but it is not required
for the internalization of the mutated EGFR receptors. Instead, USP17 depletion alters the localization of these
receptors within the cell, and although it does not decrease basal EGFR activation, it potently reduces activation of
Src, a key kinase in mutant EGFR-dependent tumorigenicity. Finally, we demonstrate that USP17 depletion can
trigger apoptosis in EGFRWT NSCLC cells, when combined with the EGFR tyrosine kinase inhibitor (TKI) gefitinib.
Conclusions: Our data reveals that USP17 facilitates trafficking and oncogenic signaling of mutant EGFR and
indicates targeting USP17 could represent a viable therapeutic strategy in NSCLC tumours carrying either an EGFR
activating mutation, or a resistance gatekeeper mutation.
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Background
The addition of ubiquitin to substrate proteins, either as
a monomer, or part of a poly-ubiquitin chain, is now
widely recognized as one of the most influential
post-translational modifications within cells. Ubiquitina-
tion can have diverse effects on substrate proteins, in-
cluding targeting them for proteasomal or lysosomal
degradation, as well as influencing their protein-protein
interactions, activation, or location within the cell [1].
This process can also be reversed by deubiquitinases
(deubiquitinating enzymes) which remove the ubiquitin
monomer, or ubiquitin chains. Six families of deubiquiti-
nases consisting of at least 97 members have now been
identified [2].
The DUB/ubiquitin specific protease 17 (USP17) fam-
ily of deubiquitinases were originally identified in mice
(DUB-1, DUB-1A, DUB-2) [3, 4]. The expression of the
human homologue, USP17/DUB-3/Dub3 (subsequently
referred to as USP17), is induced in response to cyto-
kines, chemokines and epidermal growth factor (EGF)
stimulation [5–8]. We have also shown that USP17 ex-
pression is required for proper G1 to S cell cycle
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progression [9] and chemokine driven (IL-8, SDF1) cell
motility [7]. In addition, our group and others have
shown that USP17 is overexpressed in a range of tumors
when compared to normal tissue (Non-small cell lung
cancer (NSCLC), ovarian, breast, colon, esophagus, cer-
vical, osteosarcoma) [9–14]. USP17 expression levels are
also associated with poor prognosis and metastases in
NSCLC, osteosarcoma and ovarian tumours [12–14].
Moreover, USP17 has been proposed as a potential
therapeutic target as its depletion can inhibit the growth
and migration of multiple cancer cell types, as well as in
vivo tumour models [7, 9–16].
Epidermal growth factor receptor (EGFR) is
over-expressed in many NSCLCs (~ 60%) and tyrosine
kinase activating mutations of EGFR are present in a sig-
nificant proportion of patients (10% in Caucasian popu-
lations and 30–40% in Asian populations) [17], and of
these mutations ~ 90% are either a deletion of exon 19
(in-frame), or a point mutation in exon 21 (L858R) [18,
19]. This led to the development of a range of EGFR
tyrosine kinase inhibitors (TKIs) (e.g. erlotinib, gefitinib),
and other agents such as cetuximab, aimed at inhibiting
EGFR [20]. EGFR TKIs are effective against tumors exhi-
biting EGFR activating mutations, with a response rate
of 60–80% [20]. However, these patients rapidly develop
resistance, rendering these drugs ineffective within 1–
2 years [20]. There are a wide range of resistance mecha-
nisms to EGFR inhibition identified, but in NSCLC it is
mainly due to the acquisition of the EGFR T790M gate-
keeper mutation (~ 60%) in the ATP binding pocket of
the EGFR kinase domain, with the second most com-
mon resistance mechanism being the amplification of
the hepatocyte growth factor receptor (MET) gene (10–
20%) [17]. Second generation EGFR TKIs, such as afati-
nib, initially showed promising results against cells bear-
ing the EGFR T790M mutation, but ultimately proved
no more effective than first generation drugs [21]. How-
ever, third-generation EGFR TKIs, such as osimertinib,
now appear to be able to overcome the EGFR T790M
mutation, although combination trials trying to over-
come other resistance mechanisms have so far failed
[21]. Therefore, the identification of alternate targets
which can help a larger proportion of NSCLC patients,
complement the EGFR TKIs, or combat EGFR TKI re-
sistance, are still a major priority.
Previously, we demonstrated that USP17 expression is
required for clathrin-mediated endocytosis (CME) of
EGFR [8]. As mutant EGFRs are constitutively internal-
ized [22, 23] and appear to preferentially undergo CME
[22], we hypothesized that blocking CME of mutant
EGFRs by depleting USP17 would impede their internal-
isation and oncogenic signaling. Other studies have
shown that blocking EGFR endocytosis enhances the ef-
ficacy of the EGFR TKI gefitinib in EGFRWT NSCLC
cells [24]. Suppression of EGFR endocytosis, when com-
bined with gefitinib, significantly inhibited in vitro and
in vivo growth of EGFRWT NSCLC cells, and prompted
a large proportion of EGFRWT NSCLC cells to undergo
apoptosis [24]. Therefore, we also hypothesized that
blocking EGFR CME in NSCLC cells by depleting
USP17 could enhance the efficacy of gefitinib in
EGFRWT NSCLC cells.
In this study, we demonstrate that USP17 depletion
blocks the growth of NSCLC cells which express acti-
vated and EGFR TKI resistant EGFR mutants. In
addition, although USP17 depletion does block CME in
these cells, it does not block internalisation of the EGFR
mutants, even though it does alter their downstream sig-
naling. We also demonstrate that USP17 depletion pref-
erentially triggers apoptosis in NSCLC cells that bear
EGFR activating mutations. Finally, we show that USP17
depletion can enhance the efficacy of EGFR TKIs toward
EGFRWT NSCLC cells and trigger apoptosis of these
cells. This data indicates USP17 represents a potentially
exciting therapeutic target in EGFRMT NSCLC tumors,
even those that have developed EGFR TKI resistance. In
addition, in combination with EGFR TKIs, targeting
USP17 can also potentially be used to treat EGFRWT
NSCLC tumors.
Methods
Materials
Gefitinib (ZD1839) was purchased from SelleckChem
(Suffolk, UK). Biotinylated transferrin was purchased
from Sigma.
Plasmids
The pSUPER-USP17shRNA (USP17 shRNA1; target se-
quence 5’-GCAGGAAGATGCCCATGAA-3′), pRS-USP17
shRNA (USP17 shRNA2; target sequence 5’-GATGATTTG
GCTCCTGTGGCAAGACAGCT-3′) and pRS-scrambled
shRNA were previously described [7, 8].
Cell culture and DNA transfections
A549 cells (American Type Culture Collection (ATCC),
Manassas, USA) were grown in DMEM supplemented
with 10% FCS, 1% penicillin (10,000 U/ml) /strepto-
mycin (10,000 μg/ml), and 1% L-glutamine (200 mM)
(Life Technologies-Gibco, Paisley, UK). H1975 and
HCC827 cells (American Type Culture Collection
(ATCC), Manassas, USA) were grown in RPMI-1640
supplemented with 10% FCS, 1% penicillin (10,000 U/ml)
/streptomycin (10,000 μg/ml), and 1% L-glutamine
(200 mM) (Life Technologies-Gibco, Paisley, UK). Cells
lines were grown at 37 °C in a 5% CO2 humidified
incubator.
Cells were transfected with Xtreme-GENE HP ™ trans-
fection reagent (Roche Diagnostics, Indianapolis, USA)
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according to manufacturer’s instructions. Cells were
seeded between 0.5 × 106 and 1.0 × 106 cells for cell cycle
analysis or protein experiments or 0.7–2.5 × 104 on
4-well glass culture slides (BD Falcon, Bedford, USA) for
microscopy experiments. The cells were transfected with
2 μg of plasmid DNA for protein experiments and bio-
logical assays or 0.25 μg of plasmid DNA for confocal
microscopy experiments. For those experiments with
EGF stimulation, cells were rested for 3 h in DMEM
medium without serum. Cells were then stimulated with
0.32 nM recombinant human EGF (Invitrogen-Gibco,
Maryland, USA) for the indicated times in the figures,
corresponding to the low (2 ng/mL) EGF concentrations
previously used [8, 25].
Confocal microscopy
Cells were seeded at 0.7–2.5 × 104 cells/1.7 cm2 well of
glass culture slides (BD Falcon, Bedford, USA). Cells
were transfected as previously described. The cells were
fixed in 4% parafomaldehyde (Sigma-Aldrich, Steinheim,
Germany), in PBS for 20 min. The cells were then
permeabilized in 0.5% Triton X-100 in PBS for 5 min,
washed in PBS and blocked in blocking solution (1%
BSA, 10% donkey serum [both from Sigma, St. Louis,
USA] in PBS) for 1 h at RT. Transfected proteins and
cell organelles were stained with appropriate antibodies
or counter stains according to manufacturer’s protocol.
Antibodies and co-stains were as follows: mouse
anti-EGFR (GR01L, 1:1000, Merck-Calbiochem, Darm-
stadt, Germany), mouse anti-transferrin receptor (1:100,
Invitrogen, Camarillo, USA), donkey anti-mouse Alexa
Fluor 488 (1:200, Invitrogen-Molecular Probes, Eugene,
USA). The slides were sealed with a coverslip and Pro-
long Gold antifade mounting media with DAPI (Life
Technologies-Molecular Probes, Eugene, USA). Slides
were viewed on a Leica SP8 Confocal Microscope. Fluor-
escent images were captured with a 63x lens zoomed
1-4x with a 1024 × 1024 frame and 400 Hz scanning
speed. Images were analyzed using Leica LAS X soft-
ware. The images presented in the same figures were
captured using standardized setting and exposure times.
FACS analysis
Cells were incubated with anti-EGFR monoclonal anti-
body (1:50; BD Biosciences) for 60 min at 4 °C. A mouse
IgG1 (BD Biosciences) was used as isotype-matched
control. Cell surface expression samples were analysed
by FACS Acuri Plus (BD Biosciences). Apoptosis was
evaluated using propidium iodide (PI) staining [26]. Cells
were trypsinized, fixed in ethanol for 1 h at 4 °C, stained
with propidium iodide (PI) solution (10 μg/mL) with
RNase A (250 μg/mL), incubated at 37 °C for 30 min,
and analysed by FACS Calibur (BD Biosciences) and
FlowJo software.
RNA extraction and reverse transcription-PCR
RNA was extracted using STAT-60 according to the manu-
facturer’s instructions (Tel-Test Inc., Friendswood, USA).
Reverse transcription-PCR (RT-PCR) was performed on
1 μg of total RNA using ImProm-II Reverse Transcription
System (Promega, Madison, USA) as described previously
[8]. The following primers were used: USP17, 5′-CAGT
GAATTCGTGGGAATGGAGGACGACTCACTCTAC-3′
(forward) and 5′-AGTCATCGATCTGGCACACAAGCA
TAGCCCTC-3′ (reverse). B2M 5’-GTATGCCTGCCGTG
TGAAC-3′ (forward) and 5′- AAAGCAAGCAAGCA
GAATTTGG-3′ (reverse).
Cell lysis and immunoblotting
Cells were lysed in the following buffer: 25 mM TrisHCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS, supplemented with phenylmethylsulphonyl
fluoride (1 mM), aprotinin (1.7 μg/ml) and leupeptin
(10 μg/ml). Lysates were left on ice for 20 mins, centri-
fuged at 15,000 x g for 10 min at 4 °C. Equal volumes of
whole cell lysate were added to Laemlli buffer to a final
concentration of 1X with 5% β-mercaptoethanol (Sigma,
Germany). The samples were boiled for 5 min at 99 °C for
protein denaturation. The samples were analyzed by
SDS-PAGE and Western blotting on PVDF membrane
(Millipore, Waterford, UK). The membranes were then
blocked in appropriate blocking agent, either 5% marvel
or 3% BSA, in 0.1% Tween-20/PBS for 1 h. After blocking,
the membranes were probed with the indicated antibodies
for 1 h at RT or overnight at 4 °C. The following primary
antibodies were used: rat anti-tubulin (1:10000, Abcam,
Cambridge, UK), mouse anti-ERK, mouse anti-pERK1/2
(Thr202/Tyr204), rabbit anti-Src, rabbit anti-pSrc
(Tyr416), rabbit anti-AKT, rabbit anti-pAKT (Ser473),
rabbit anti-pEGFR (Tyr1068), rabbit anti-cleaved PARP,
rabbit anti-cleaved caspase 3, mouse anti-caspase 9, rabbit
anti-BCL-2 (1:1000, Cell Signaling, Danvers, USA), mouse
anti-EGFR (BD Biosciences, USA). The membrane was
incubated with the appropriate secondary antibody:
either goat anti-mouse HRP conjugate or goat
anti-rabbit HRP conjugate (both diluted 1:10,000,
BioRad, Hertfordshire, UK) or rabbit anti-rat HRP
conjugate (1:40,000, Abcam, Cambridge,UK). Proteins
were detected with a chemiluminescence protocol and
were exposed using the ChemiDoc XRS+ imaging
system (BioRad, Hercules, USA).
MTT assay
Cell viability was determined using 3-(4,5-dimethylthiazo-
l-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) [27].
Representative results of at least 3 independent experi-
ments are shown.
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Caspase activity assay
Caspase activity was measured by a fluorogenic substrate
assay. Ac-DEVD-AMC substrate (Enzo) were used to de-
tect the activity of caspase 3/7, according to manufac-
turer’s instructions.
Clonogenic survival assay
To determine the effects of USP17 depletion on cell
proliferation, cells were transfected as described. The
following day, transfected cells were trypsinised and
reseeded on 6-well plates. After 72 h, the growth
medium was replaced with fresh medium and cells were
allowed to grow for a further 11 days. Colonies were
visualized by crystal violet staining. Representative re-
sults of at least 3 independent experiments are shown.
Statistical analysis
Student’s t-tests and 2-way ANOVA were calculated using
the GraphPad software (Prism5). 2-way ANOVA test was
used to determine the significance of changes in localisa-
tion, cell number, cell viability, and clonogenic survival,
and were described as significant having P values that
were considered significant * < 0.05, ** < 0.01, *** < 0.001.
P values of > 0.05 were considered non-significant (ns).
Results
USP17 is required for NSCLC cell proliferation and colony
formation, independent of the EGFR mutational status
USP17 is overexpressed in NSCLC and its expression
levels are associated with poor prognosis and metastases
[13]. USP17 depletion has also been shown to inhibit the
growth and migration of NSCLC cells, suggesting it rep-
resents a potential therapeutic target in NSCLC [11].
However, this study only examined EGFRWT NSCLC
cells and did not assess the impact of USP17 in cells
with EGFR activating mutations [11]. Therefore, as we
have shown that USP17 is required for EGFR CME [8],
and mutant EGFR preferentially undergoes CME pro-
moting its recycling and its oncogenic activity [22], we
wanted to examine if the impact of USP17 depletion
would be more potent in EGFRMT NSCLC cells.
To assess the impact of USP17 on NSCLC proliferation,
we transfected A549 (EGFRWT), HCC827 (DelE746-A750)
and H1975 (L858R/T790M) cells with either of two vali-
dated USP17 specific shRNAs (shRNA1 and shRNA2)
(Fig. 1A/B/C) [7–9] or a non-targeting shRNA. The impact
on cell viability of depleting USP17 was examined by MTT
and trypan-blue exclusion assay. USP17 depletion signifi-
cantly reduced A549 (Fig. 1D, G), HCC827 (Fig. 1E, H) and
H1975 (Fig. 1F, I) cell numbers and viability, indicating that
USP17 is required for the proliferation of NSCLC cells in-
dependent of the EGFR mutational status.
We next examined the impact of USP17 depletion on col-
ony formation (Fig. 1J-L). Survival fractions were calculated
using the non-targeting shRNA control as 100%. It was clear
that USP17 depletion significantly reduced the ability of all
the NSCLC cells (A549, HCC827, H1975) (Fig. 1J-L) to form
colonies. Again, this indicates USP17 depletion reduces pro-
liferation independent of the EGFRmutational status.
USP17 alters the localization of mutant EGFRs in NSCLC
cells
We have previously demonstrated that USP17 is required
for EGFR CME [8]. However, although it is known that mu-
tant EGFRs constitutively internalize and preferentially
undergo CME [22], it is unclear what role USP17 plays.
Therefore, to investigate if USP17 is required for the endo-
cytosis and trafficking of mutant EGFRs in NSCLC cells we
transfected the HCC827 and H1975 cells with shRNAs
targeting USP17 and examined the localisation of EGFR
using an anti-EGFR antibody after 15 min 2 ng/ml EGF
treatment (Fig. 2). EGFR subjected to low concentrations
(< 2 ng/ml) of EGF are internalized via CME and this is the
physiologically relevant concentration in tumours [28]. In
both the HCC827 (Fig. 2A, C) and H1975 (Fig. 2B, D) cells,
EGFR was observed on the plasma membrane and intracel-
lular vesicles throughout the cell in the control cells.
Unexpectedly, upon USP17 depletion, in both the HCC827
(Fig. 2A, C) and H1975 (Fig. 2B, D) cells, EGFR was still
predominantly observed on intracellular vesicles, as well as
the plasma membrane. However, the location of the vesicles
bearing EGFR in both the HCC827 and H1975 cells ap-
peared to shift to a more perinuclear localization upon
USP17 depletion (Fig. 2A-B). This perinuclear localisation
was remarkably similar to that observed in USP17 depleted
cells treated with high EGF concentrations (> 2 ng/ml)
which bypass the CME block by instead using
clathrin-independent endocytosis routes [8]. The observa-
tion that these EGFR mutants were not trapped at the cell
surface upon USP17 depletion was also confirmed by stain-
ing non-permeabilised cells for cell surface EGFR and
analyzing them by flow cytometry (Fig. 2C-D). In addition,
we transfected A549 (EGFRWT) as indicated and stained
non-permeabilised cells for cell surface EGFR to confirm
USP17 depletion blocked EGFR CME (Fig. 2E). As reported
previously [8], USP17 depletion caused a marked
re-localisation of EGFR to the PM in these cells.
Therefore, to confirm that USP17 depletion was actually
blocking CME in the HCC827 and H1975 cells, we next
examined the localisation of transferrin receptor (TfR),
which is internalized almost exclusively by CME, using an
anti-TfR antibody (Fig. 3). In both HCC827 (Fig. 3A-B)
and H1975 (Fig. 3C-D) cells, TfR was predominantly ob-
served on intracellular vesicles in the controls cells. How-
ever, upon USP17 depletion, TfR in both the HCC827
(Fig. 3A-B) and H1975 (Fig. 3C-D) cells was now observed
predominantly at the plasma membrane. As TfR can only
internalize via CME, this confirmed that USP17 depletion
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Fig. 1 (a-c) A549, HCC827, and H1975 cells were transfected as indicated and 72 h post-transfection USP17 mRNA expression was assessed by
RT-PCR. B2M mRNA expression was also assessed as a loading control. (d-f) Equivalent numbers of A549, HCC827, and H1975 cells were
transfected as indicated and 72 h post-transfection, the number of viable cells was determined by trypan-blue exclusion assay. (g-i) Equivalent
numbers of A549, HCC827, and H1975 cells were transfected as indicated and 72 h post-transfection, cell viability was determined by MTT assay
and the results reported as % of control. (j-l) A549, HCC827, and H1975 cells were transfected as indicated and 24 h post-transfection, equivalent
numbers of cells were re-plated and subsequently incubated for a further 11 days. Colony numbers were then assessed and plotted as the
survival fraction in comparison to control. Representative images are included in the bottom panels. ** p < 0.01, *** p < 0.001
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blocks CME in HCC827 and H1975 cells. Therefore, this
indicated that USP17 depletion was blocking CME in both
cell lines, but rather than being trapped at the cell surface
like wild type EGFR, the mutants shift to an alternative
endocytosis pathway, allowing them to traffic to endo-
somes where they can trigger intracellular signaling.
USP17 is required for Src activation by mutant EGFR
The observation that USP17 depletion in the
HCC827 and H1975 cells resulted in altered mutant
EGFR trafficking led us to examine if this was alter-
ing the downstream signaling from these mutant
receptors.
A
C D E
B
Fig. 2 (a) HCC827 cells were transfected as indicated. 72 h post transfection the cells were starved in serum free medium for 3 h prior to
incubation with 0.32 nM recombinant EGF. After 15 min the cells were fixed and stained using an anti-EGFR antibody (green) and EGFR
localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom panels are enlarged images of the
indicated area in the upper panels. Scale bar = 10 μm. (b) H1975 cells were transfected as indicated. 72 h post transfection the cells were starved
in serum free medium for 3 h prior to incubation with 0.32 nM (2 ng/ml) recombinant EGF. After 15 min the cells were fixed and stained using
an anti-EGFR antibody (green) and EGFR localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom
panels are enlarged images of the indicated area in the upper panels. Scale bar = 10 μm. (c) HCC827 cells were transfected as indicated and 72 h
post-transfection the cells were serum starved in serum free medium for 3 h. Subsequently the cells were incubated with 0.32 nM recombinant
EGF and after 15 min, the cells were washed and stained for EGFR using an anti-EGFR FITC, for 30 min at 4 °C. After incubation cells were washed
and EGFR cell membrane expression assessed by flow cytometry using receptor-specific FITC-conjugated mAbs. Expression was compared with a
nonspecific isotype-matched control antibody. Percent of cells with fluorescent EGFR was plotted as a representative histogram. (d) H1975 cells
were transfected as indicated. 72 h post-transfection the cells were serum starved in serum free medium for 3 h. Subsequently the cells were
incubated with 0.32 nM recombinant EGF and after 15 min incubation, cells were washed and stained for EGFR using an anti-EGFR FITC, for
30 min at 4 °C. After incubation cells were washed and EGFR cell membrane expression assessed by flow cytometry using receptor-specific
FITC-conjugated mAbs. Expression was compared with a nonspecific isotype-matched control antibody. Percent of cells with fluorescent EGFR
was plotted as representative histograms. (e) A549 cells were transfected as indicated. 72 h post-transfection the cells were serum starved in
serum free medium for 3 h. Subsequently the cells were incubated with 0.32 nM recombinant EGF and after 15 min incubation, cells were
washed and stained for EGFR using an anti-EGFR FITC, for 30 min at 4 °C. After incubation cells were washed and EGFR cell membrane expression
assessed by flow cytometry using receptor-specific FITC-conjugated mAbs. Expression was compared with a nonspecific isotype-matched control
antibody. Percent of cells with fluorescent EGFR was plotted as representative histograms
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To probe the impact of USP17 depletion upon the
signaling of the EGFR mutants, we knocked down the
expression of USP17 in HCC827 and H1975 cells and
serum starved for 3 h to minimize potential signaling
crosstalk from sources other than the constitutively
active EGFR mutants. Cell lysates were separated by
SDS-PAGE and immunoblotted to determine the phos-
phorylation status of EGFR (Tyr1068), Akt (Ser473),
ERK1/2 (Thr 202/Tyr204) and Src (Tyr416). Total
protein levels were also assessed to determine if USP17
depletion impacted upon the stability of each protein.
USP17 depletion was found to enhance the activation of
EGFR, Akt and ERK1/2 in NSCLC cells expressing both
EGFR DelE746-A750 (Fig. 4A) and EGFR L858R/T790 M
(Fig. 4B). This correlated with our previous finding that
USP17 depletion prolonged ERK1/2 activation upon
stimulation of wild type EGFR [8] and indicates USP17 ex-
pression is not required for EGFR activation. In addition,
as USP17 depletion does not impact upon EGFR
protein levels, it also indicates its depletion does not
reroute mutant EGFR receptors to the lysosome for
degradation. USP17 depletion had little impact upon
the protein levels of EGFR and ERK1/2, but Akt
protein levels increased upon USP17 depletion in
both cell lines (Fig. 4A-B). In contrast, Src (Tyr416)
activation was dramatically reduced upon USP17
depletion in both HCC827 and H1975 cells, whilst
Src protein levels were unaffected (Fig. 4A-B).
Taken together, this data clearly demonstrated that
these EGFR mutants remained active in the absence
of USP17, but that their signaling profile was altered,
probably as a result of the alternative trafficking.
A B
C D
Fig. 3 (a) HCC827 cells were transfected as indicated and 72 h post transfection the cells were starved in serum free media for 30 mins prior to
incubation with 25 μg/mL transferrin (Sigma). After 15 min the cells were fixed and stained using an anti-transferrin antibody (green) and transferrin
localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom panels are enlarged images of the indicated
area in the upper panels. Scale bar = 10 μm. (b) At least 50 cells per condition were blindly scored for three separate experiments based on the plasma
membrane localisation of transferrin receptor. (c) H1975 cells were transfected as indicated and 72 h post transfection the cells were starved in serum
free media for 30 mins prior to incubation with 25 μg/mL transferrin (Sigma). After 15 min the cells were fixed and stained using an anti-transferrin
antibody (green) and transferrin localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom panels are
enlarged images of the indicated area in the upper panels. Scale bar = 10 μm. (d) At least 50 cells per condition were blindly scored for three separate
experiments based on the plasma membrane localisation of transferrin receptor. ** p < 0.01, *** p < 0.001
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USP17 depletion triggers apoptosis in NSCLC cells with
EGFR mutations
Our initial experiments demonstrated a reduction in the
viability of the EGFRMT NSCLC cells upon USP17
depletion (Fig. 1), but the assays used didn’t specify
between a cytostatic or cytotoxic effect. Therefore, as
inhibition of Src in EGFR-dependent NSCLC cell lines
has previously been shown to induce apoptosis [29], we
hypothesized that the observed reduction in Src activa-
tion (Fig. 4) could be triggering a similar effect. We
transfected HCC827 and H1975 cells as before and
immunoblotted lysates taken after 48 h for markers of
apoptosis, specifically those which Src has previously
been shown to regulate [30–34]. Immunoblotting
revealed that when USP17 is depleted in HCC827 and
H1975 cells, levels of cleaved PARP, caspase 9 and
caspase 3 (Fig. 5A, C), as well as caspase 3/7 activity
(Fig. 5B, D), increased. In addition, the levels of the
anti-apoptotic protein BCL-2 were reduced, signifying a
reduction in the apoptotic threshold of these cells.
(Fig. 5A, C). These results indicated that, in both the
HCC827 and H1975 cells, depletion of USP17 triggered
the initiation of apoptosis, something which correlates
with the observed reduction in Src activation.
USP17 depletion results in apoptosis when combined
with EGFR TKIs in EGFRWT NSCLC cells
EGFR TKIs have been shown to be effective against tu-
mours exhibiting EGFR activating mutations, but lack
efficacy in tumours without these mutations [20]. However,
blocking both clathrin-dependent and clathrin-independent
endocytosis has previously been shown to enhance the
efficacy of the EGFR TKI gefitinib towards NSCLC cells
expressing EGFRWT, and prompt increased levels of
apoptosis when combined with gefitinib treatment [24].
Therefore, we wanted to determine if blocking CME in
EGFRWT NSCLC cells by depleting USP17 could also
enhance the efficacy of gefitinib towards these cells.
To probe this, we transfected A549 cells as before, with
either the USP17 specific shRNAs, or a non-targeting
shRNA. 48 h post-transfection, the cells were treated with
the indicated doses of gefitinib for a further 48 h and the
viability of these cells assessed by MTT assay. USP17 de-
pletion resulted in a significant drop in cell viability, and
the combination of USP17 depletion and a range of gefi-
tinib doses resulted in a drop in viability, compared to
either gefitinib or USP17 depletion alone (Fig. 6A). This
was demonstrated in particular using the combination of
USP17 depletion and a 10 μM gefitinib dose which
showed a significant drop in viability in the combination
when compared to either alone (Fig. 6B). This indicated
that USP17 depletion improves the efficacy of gefitinib in
EGFRWT NSCLC cells. However, the previous study also
indicated that blocking endocytosis in combination with
gefitinib treatment could trigger a significant increase in
apoptosis [24], and therefore we investigated if USP17 de-
pletion could also do this. We transfected the A549 cells
as before and immuno-blotted lysates taken after 48 h for
A B
Fig. 4 (a) HCC827 cells were transfected as indicated. 72 h post transfection the cells were starved in serum free medium for 3 h. Whole cell
lysates were harvested and levels of phosphorylated Erk1/2, Akt, Src and EGFR were assessed by immuno-blotting using anti-pERK1/2, anti-pAkt,
anti-pSrc and, anti-pEGFR (Tyr1068). Total protein levels of Erk, Akt, Src and EGFR were also assessed in addition to α-tubulin, utilising Erk1/2, Akt,
Src, EGFR and anti-tubulin antibodies. (b) H1975 cells were transfected as indicated. 72 h post transfection the cells were starved in serum free
medium for 3 h. Whole cell lysates were harvested and levels of phosphorylated Erk1/2, Akt, Src and EGFR were assessed as before. Total protein
levels of Erk, Akt, Src and EGFR were also assessed in addition to α-tubulin, as before
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cleaved PARP (Fig. 6C). USP17 depletion, or gefitinib
treatment, didn’t have a marked impact upon the levels of
PARP cleavage. However, combining USP17 depletion
with gefitinib treatment resulted in a marked increase in
the levels of cleaved PARP (Fig. 6C). This impact was
further confirmed by cell cycle analysis using propidium
iodide staining. USP17 depletion and gefitinib treatment
both led to small increases in the proportion of sub G1
phase cells (apoptotic cells) (Fig. 6D). The combination of
USP17 depletion and gefitinib treatment led to a signifi-
cant rise in the number of sub G1 phase cells, indicating a
significant rise in the proportion of cells undergoing apop-
tosis (Fig. 6C). These results indicated that combining
USP17 depletion with gefitinib treatment markedly im-
proved the efficacy of gefitinib in these EGFRWT NSCLC
cells leading to an increase in cell death.
Discussion
The data presented here demonstrates that depleting
USP17 can not only block the proliferation of NSCLC
cells which are EGFRWT, but also NSCLC cells bearing
activating mutations of EGFR, as well as those with
secondary gatekeeper EGFR mutations. In addition, al-
though USP17 depletion did block CME within these
cells, as demonstrated through the loss of TfR endocyto-
sis, it did not block the endocytosis of the activated
EGFR mutants (DelE746-A750 or L858R/T790M). How-
ever, USP17 depletion did alter the localization and
downstream signaling of these EGFR mutants, and in
particular blocked their activation of Src. As a result,
USP17 depletion preferentially triggered apoptosis in
NSCLC cells bearing EGFR mutations. In addition, when
combined with EGFR TKI treatment, USP17 depletion
could induce apoptosis in EGFRWT NSCLC cells, indi-
cating USP17 inhibition can improve the efficacy and
expand the susceptible patient cohort for these drugs.
USP17 is required for EGFR CME [8] and as mutant
EGFRs are constitutively internalized and appear to pref-
erentially undergo CME and recycling [22], we hypothe-
sized that USP17 would be necessary for the endocytosis
and oncogenic function of EGFR mutants. USP17 deple-
tion did not block their endocytosis, but it did appear to
A B
C D
Fig. 5 (a/c) HCC827 and H1975 cells were transfected as indicated. 48 h post transfection, whole cell lysates were harvested and levels of cleaved
PARP, cleaved caspase 9, cleaved caspase 3, and BCL-2 were assessed by immuno-blotting using anti-cleaved PARP, anti-caspase 9, anti-cleaved
caspase 3, anti-BCL-2, in addition to α-tubulin, as a loading control. (b/d) HCC827 and H1975 cells were transfected as indicated. Caspase-3/7
activity levels were assessed 48 h post-transfection. ** p < 0.01, *** p < 0.001
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alter the localization of both the DelE746-A750 and
L858R/T790M mutant EGFRs to a more peri-nuclear
vesicular pattern which was reminiscent of that previ-
ously observed for EGFR when high dose EGF was
utilised in the absence of USP17 [8]. As a result, we
propose these constitutively active EGFR mutants mimic
‘high-dose EGF’, resulting in their internalisation via
non-clathrin modes of entry when USP17 is depleted.
Mutant EGFRs have been shown to display altered
endocytic trafficking, undergoing ligand independent
trafficking to the endocytic recycling compartment
(ERC), rather than being sent to the lysosome for de-
struction [22, 23]. The aberrant trafficking allows them a
preferential interaction with Src, which contributes to
their oncogenic activity [22], and the observed loss of
Src activation and proliferation, as well as the initiation
of apoptosis, would indicate USP17 is vital for the aber-
rant trafficking of EGFR DelE746-A750 and EGFR
L858R/T790M mutants. It also indicates that in the
absence of USP17 these mutants do not traffic to the
compartment where they interact with Src, and thus
they no longer can sustain their oncogenic activity, even
though the mutants are themselves still active. Indeed,
this would tie in with the previous literature which has
shown that Src inhibition in EGFR-dependent NSCLC
cell lines results in a shutdown of the EGFR-dependent
survival network and induces apoptosis [29].
There are several reported modes of non-clathrin medi-
ated endocytosis which have been shown to be critical for
attenuating EGFR signaling by trafficking EGFRs for
A D
B
C
Fig. 6 (a) A549 cells were transfected as indicated and 24 h after transfection cells were treated with the indicated dose of EGFR TKI (gefitinib) for
48 h. Cell viability was determined using an MTT assay and the results are plotted as % of untreated and un-transfected control. (b) A549 cells were
transfected as indicated and 24 h after transfection, cells were treated with IC50 dose of EGFR TKI (10 μM) gefitinib for 48 h. Cell viability was
determined using an MTT assay and the results are plotted as % of untreated and un-transfected control. (c) A549 cells were transfected as indicated
and treated as before with the EGFR TKI (10 μM) gefitinib for 48 h. Whole cell lysates were harvested and PARP cleavage analysed by Western blotting.
α-tubulin was used as a loading control. (d) A549 cells were transfected as indicated and treated as before with the EGFR TKI (10 μM) gefitinib for 48 h.
The cells were fixed and cell cycle analysis was carried out by staining the cells with propidium iodide before assessment by flow cytometry (Upper
panels). The percentage of cells in SubG1 (apoptotic cells) for each condition is plotted in a bar graph (Lower panel). ** p < 0.01, *** p < 0.001
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lysosomal degradation. These include a pathway dependent
on the function of the ER protein reticulon 3 (RTN3), a
macropinocytic-like pathway, and fast endophilin-mediated
endocytosis (FEME) [35]. It is unclear which, if any, of these
pathways are utilized by the EGFR mutants in the absence
of USP17, and why this doesn’t result in turnover of the
receptor in the lysosome. However, it has been suggested
that the L858R mutant has impaired Cbl recruitment and
that this encourages hetero-dimerization with ErbB2 and
hinders its trafficking to the lysosome [35]. In addition, it is
unclear why we see increased EGFR, ERK1/2 and Akt
activation in the absence of USP17. It has been reported
that PTP1B can dephosphorylate EGFR at the recycling
endosome and thus limit EGFR activation and signaling
[36]. Therefore, as these mutant EGFRs undergo ligand
independent trafficking to the ERC via CME [22, 23], this
could explain the increase in activation, as it will block
PTP1B access and thus dephosphorylation of these EGFR
mutants. This would further support the theory that in the
absence of USP17 these EGFR mutants fail to traffic to the
ERC, something which also correlates with the loss of Src
activation, as these EGFR mutants have been shown to
interact with Src in the ERC [22]. In regard to the alteration
in Akt levels, as well as activation, this was a consistent
observation, but there is no obvious explanation and
further examination of this is required to determine why
USP17 impacts upon Akt stability.
Other work had previously indicated that blocking
EGFR endocytosis enhances the efficacy of gefitinib to-
wards EGFRWT NSCLC cells, with an endocytosis block
and gefitinib combination significantly inhibiting growth
both in vitro and in vivo, as well as prompting a large pro-
portion of the cells to undergo apoptosis [24]. We hypoth-
esized that depleting USP17 could potentially garner a
similar impact upon EGFRWT NSCLC cells, something
which was backed up by the data obtained. Indeed, deplet-
ing USP17 in combination with gefitinib had a greater
impact upon EGFRWT NSCLC cells than either alone.
Moreover, the combination of USP17 depletion and gefi-
tinib preferentially triggered apoptosis, indicating this can
enhance the efficacy of this drug in these cells.
Conclusions
The data presented here indicates that inhibiting USP17
potentially represents a promising therapeutic strategy in
NSCLC for a number of reasons. First of all, USP17 is
overexpressed in NSCLC [9, 11, 13] and its expression
levels are associated with poor prognosis and metastases
in NSCLC [13]. Next, USP17 depletion blocks the prolifer-
ation of NSCLC cells regardless of the EGFR mutational
status, indicating that USP17 inhibition could represent
an opportunity to target the tumors of a large proportion
of NSCLC patients. In addition, as depleting USP17 in
NSCLC cells harboring EGFR activating mutations
triggers their apoptosis, this indicates inhibiting USP17
may be of particular benefit in these tumors, which repre-
sent at least 10% of all NSCLC patients [17]. Also, the
observation that ~ 90% of the EGFR mutants are either
the exon 19 deletion, or L858R mutations [18, 19] used
here, would again indicate USP17 represents an interest-
ing therapeutic option. More interestingly, resistance to
EGFR TKIs in NSCLC is mainly mediated via the acquisi-
tion of the EGFR T790M gatekeeper mutation (~ 60%)
[17], and we have shown here that getting rid of USP17
can trigger apoptosis of NSCLC cells with this mutation.
This would indicate targeting USP17 represents an inter-
esting complement to EGFR TKIs, to prevent resistance,
or act as an alternative once resistance is established.
Finally, the observation that depleting USP17, in combin-
ation with gefitinib, triggers EGFRWT NSCLC cells to
undergo apoptosis, indicates targeting USP17 in combin-
ation with an EGFR TKI could greatly expand the efficacy
of these drugs in the NSCLC patient population.
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